Elsa Kalbacher

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Florence Duffaud, Olivier Mir, Pascaline Boudou‐Rouquette et al. · The Lancet Oncology · 2018 · 304 citations

Oncology, Adult Patients, Metronomic Therapy +8

Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas

Antoîne Italiano, Angela Cioffi, Nicolas Penel et al. · Cancer · 2011 · 151 citations

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Bradley J. Monk, Rachel N. Grisham, Susana Banerjee et al. · Journal of Clinical Oncology · 2020 · 144 citations · Full text

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara et al. · New England Journal of Medicine · 2024 · 116 citations · Full text

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann et al. · The Lancet Oncology · 2022 · 110 citations

Unresectable Leiomyosarcoma, First-line Therapy, Surgical Oncology +7